Work

Differential Site-Based Expression of Pentose Phosphate Pathway-Related Proteins among Breast Cancer Metastases

Year: 2017

Type: article

Abstract: Purpose. We aimed to investigate the expression of pentose phosphate pathway- (PPP-) related proteins in metastatic breast cancer and its relationship with clinicopathologic factors.Methods. Tissue samples from 126 metastatic breast cancers were included in a tissue microarray. Expression of PPP-related proteins [glucose-6-phosphate dehydrogenase (G6PDH), 6-phosphogluconolactonase (6PGL), 6-phosphogluconate dehydrogenase (6PGDH), and nuclear factor erythroid 2-related factor (NRF2)] was determined by immunohistochemistry.Results. G6PDH ( p=0.011 ) and cytoplasmic NRF2 ( p=0.001 ) showed the highest expression in brain metastases. Human epidermal growth factor receptor (HER-2) positivity was associated with G6PDH ( p<0.001 ) and cytoplasmic NRF2 ( p=0.015 ) positivity. A high Ki-67 labeling index (LI) was correlated with nuclear NRF2 positivity ( p=0.037 ), and HER-2-positive luminal B type was associated with G6PDH positivity ( p=0.001 ). On multivariate Cox analysis, independent risk factors of short overall survival were 6PGL positivity in bone metastasis (HR 4.180, 95% CI 1.160–15.06, p=0.029 ) and low Ki-67 LI in lung metastasis (HR 11.853, 95% CI 1.841–76.30, p=0.009 ).Conclusion. Differential expression of PPP-related proteins correlated with different prognoses and metastatic sites, with the highest expression in brain metastases, and could be a potential therapeutic target.

Source: Disease Markers

DOI: 10.1155/2017/7062517

Authors: Yoon Jin Cha, Woo Hee Jung, Ja Seung Koo

Institutions: Yonsei University, Gangnam Severance Hospital, Severance Hospital, Yonsei University Health System

Language: English

Topic: Cancer, Hypoxia, and Metabolism

Subfield: Cancer Research

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: hybrid

Estimated APC paid: $2,550